RDGL · Vivos Inc · Financials
Substantial doubt about the company's ability to continue as a going concern.
“The independent registered public accounting firm has expressed substantial doubt about the Company's ability to continue as a going concern due to limited revenue, nominal cash, and accumulated deficits since inception. Management plans to pursue additional funding through debt and equity financing (including the pending 2026 Regulation A+ Offering), enhance operating performance via strategic focus on core products, process efficiencies, and cost structure improvements. There can be no assurance of success in raising working capital or achieving profitable operations, and the financial statements include no adjustments for outcomes of this uncertainty.”View the 10-Q filed Aug 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $99.1K | $68.38K | $4995 | $19.5K | $36.5K | $14.89K | $7000 | $9500 | — | $4054 | — | — | — | — | — | — | — | |
| $73.55K | $99.03K | $74.94K | $49.58K | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $124.76K | $128.13K | $30.98K | $25.54K | $28.78K | $12K | $5608 | $6028 | — | — | $0 | $474 | $1104 | $105.33K | $72.82K | $64.04K | $70.13K | |
| -$25.66K | -$59.76K | -$2984 | -$6036 | $7720 | $2887 | $1392 | $3472 | — | — | — | — | — | — | — | — | — | |
| — | -87.39% | -59.74% | -30.95% | 21.15% | 19.39% | 19.89% | 36.55% | — | — | — | — | — | — | — | — | — | |
| $212.09K | $352.23K | $324.63K | $732.7K | $343.8K | $286.85K | $84.67K | $67.58K | $104.21K | $203.04K | $328.03K | $149.65K | $44.27K | — | — | — | — | |
| — | — | — | — | — | — | — | — | $11.5K | $111.66K | $284.14K | $0 | $1300 | $9912 | $18.31K | $58.88K | $29.07K | |
| $304.4K | $296.56K | $241.82K | $165.77K | $151.11K | $112.04K | $109.03K | $74.33K | $98.64K | $109.46K | $432.47K | $408.31K | $401.3K | $1.22M | $1.12M | $564.66K | $544.5K | |
| — | — | — | — | — | — | — | — | — | $0 | $0 | $1339 | $5832 | $8889 | $11.16K | $6668 | $5693 | |
| — | — | — | — | — | — | — | — | — | $1473 | $2947 | $5672 | $11.99K | $208.63K | $483.2K | $546.39K | $545.19K | |
| $2.8M | $3.11M | $2.6M | $2.79M | $2.53M | $2.5M | $673.91K | $1.33M | $2.49M | $2.62M | $4.44M | $2.07M | $1.98M | $3.72M | $6.12M | $2.96M | $4.09M | |
| -$2.83M | -$3.17M | -$2.6M | -$2.79M | -$2.52M | -$2.5M | -$672.52K | -$1.33M | -$2.49M | -$2.62M | -$4.44M | -$2.04M | -$1.96M | -$3.58M | -$5.87M | -$2.56M | -$3.73M | |
| — | -4628.68% | -52139.82% | -14323.83% | -6898.13% | -16805.25% | -9607.44% | -13999.78% | — | -64551.41% | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | -$2.62M | -$4.43M | -$2.04M | -$1.94M | -$3.37M | -$5.39M | -$2.02M | -$3.18M | |
| — | — | — | — | — | $25.38K | $287.47K | $261.37K | $5.65M | $3.9M | $6.26M | $3.2M | $2.46M | $1.6M | $1.1M | $408.47K | $860.25K | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $0 | $599 | |
| -$774.08K | $99.03K | -$306.06K | -$101.61K | $47.59K | -$25.97K | -$284.47K | -$280.12K | -$5.21M | -$3.8M | -$5.42M | $8.27M | -$16.15M | $108.81K | -$2.72M | -$187.75K | -$329.69K | |
| -$3.6M | -$3.07M | -$2.91M | -$2.89M | -$2.47M | -$2.53M | -$956.99K | -$1.61M | -$7.7M | -$6.42M | -$9.85M | $6.23M | -$18.11M | -$3.47M | -$8.59M | -$2.75M | -$4.06M | |
| — | — | — | — | — | $0 | $0 | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$3.6M | -$3.07M | -$2.91M | -$2.89M | -$2.47M | -$2.53M | -$956.99K | -$1.61M | -$7.7M | -$6.42M | -$9.85M | $6.23M | -$18.11M | -$3.47M | -$8.59M | -$2.75M | -$4.06M | |
| — | -4483.86% | -58267.23% | -14844.89% | -6767.75% | -16979.69% | -13671.31% | -16948.39% | — | -158330.71% | — | — | — | — | — | — | — | |
| USD/shares | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.01 | — | — | — | — | — | — | -$0.06 | -$0.03 | -$0.11 | -$0.04 | -$0.07 |
| USD/shares | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.01 | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 452.72M | 409.67M | 368.81M | 351.43M | 325.85M | 222.8M | 175.2M | 55.5M | 48.39M | 21.5M | 18.51M | 319.27M | 100.69M | 75.67M | 69.35M | 56.17M |
| shares | — | 452.72M | 409.67M | 368.81M | 351.43M | — | — | — | 444.01M | 48.39M | 21.5M | 18.51M | 13.87B | 106.74M | 62.05M | 17.13M | — |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Operating lease liabilities | 2026-06-30 | USD 103,153 | 10-Q filed 2026-08-12 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 72 similar-size Medical Devices companies (of 162 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| IsoPet | $143,025 | — |
| Services Treatments | $88,875 | $29,995 |
| Certification | $37,483 | — |
| Polymer | $1,056 | — |
| Freight | $1,050 | — |
| Discount Certifications | -$9,995 | — |
| Discount Services | -$71,815 | -$2,000 |
| Discount IsoPet | -$121,300 | — |